在运动中使用皮内注射分次剂量的灭活脊髓灰质炎疫苗:冈比亚的一项实用性、开放标签、非劣效性试验
该实用性、开放标签、非劣效性试验在冈比亚社区运动背景下,将4-59月龄儿童按疫苗接种团队随机分配至无针注射器(DSJI)、皮内适配器(IDA)或BCG针筒(N&S)三种皮内分次剂量IPV接种方式,比较2型免疫应答率。结果显示DSJI和IDA相比N&S均达到非劣效,未见安全性问题,免疫应答不受接种者经验或注射质量影响。
要点
- DSJI组2型免疫应答率90.1%,N&S组93.8%,IDA组96.6%。
- 2型血清阴性儿童全部(53/53)发生血清阳转。
- IDA和DSJI对2型、1型和3型均显示非劣效。
核心结论
- 在运动背景下,使用N&S、DSJI或IDA进行皮内分次剂量IPV接种均安全,且产生的免疫应答一致,不依赖于接种者经验或注射质量。
- 面临疫苗衍生2型脊髓灰质炎病毒暴发的国家应考虑开展分次剂量IPV运动,以提升人群免疫力并预防急性弛缓性麻痹病例。
研究设计与样本
- 实用性、开放标签、非劣效性试验,在冈比亚社区运动背景下开展,疫苗接种团队按1:1:1随机分配至三种接种方式。
- 共招募3189名4-59月龄儿童,其中3170名符合条件;3天内2720名儿童接种(N&S组917名,IDA组874名,DSJI组929名)。
- 在992名25-59月龄且有基线血清中和抗体数据的儿童中,于接种前和接种后4周测量脊髓灰质炎病毒血清中和抗体。
- 主要结局为2型免疫应答率(血清阴性[SNA滴度<8]儿童血清阳转加上血清阳性儿童滴度4倍升高),免疫原性分析按方案进行。
- 非劣效界值为-10%,计算DSJI或IDA组与N&S组免疫应答的调整差异及97.5%CI。
主要发现
- 在992名25-59月龄有基线SNA数据的儿童中,DSJI组2型免疫应答率为90.1%(95%CI 86.1-92.9;281/312),N&S组为93.8%(90.6-95.8;331/353),IDA组为96.6%(94.0-98.0;316/327)。
- 所有(53/53)2型血清阴性儿童均发生血清阳转。
- 2型脊髓灰质炎:IDA对比N&S调整差异0.7%(97.5%CI -3.3至4.7),未调整差异2.9%(-0.9至6.8);DSJI对比N&S调整差异-3.3%(-8.3至1.5),未调整差异-3.7%(-8.7至1.1),两者均显示非劣效。
- 1型和3型:IDA和DSJI对比N&S均显示非劣效。
- 注射质量及接种者培训和经验对免疫应答均无影响;未报告安全性问题。
关键数值与推荐
- 2型非劣效界值为-10%,DSJI和IDA对比N&S的调整差异97.5%CI下限均高于-10%。
- IDA对比N&S的2型调整差异0.7%(97.5%CI -3.3至4.7);DSJI对比N&S的2型调整差异-3.3%(97.5%CI -8.3至1.5)。
- DSJI组2型免疫应答率90.1%(95%CI 86.1-92.9;281/312),N&S组93.8%(90.6-95.8;331/353),IDA组96.6%(94.0-98.0;316/327)。
临床怎么用
- 作者认为,面临疫苗衍生2型脊髓灰质炎病毒暴发的国家应考虑开展分次剂量IPV运动,以提升人群免疫力并预防急性弛缓性麻痹病例。
- 原文未据此给出针对接种者经验或注射质量的具体推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A rapid increase in circulating vaccine-derived poliovirus type 2 outbreaks, and the need to reserve inactivated poliovirus vaccine (IPV) for routine immunisation, has increased the value of fractional dose IPV (fIPV) as a measure to prevent acute flaccid paralysis. However, the intradermal route of administration has been viewed as prohibitive to outbreak response campaigns. We aimed to establish the immunogenicity and safety of administering intradermal fIPV with a disposable syringe jet injector (DSJI) or an intradermal adaptor (IDA) compared with standard administration with a BCG needle and syringe (N&S). METHODS: This pragmatic, non-inferiority trial was undertaken in a campaign setting in communities in The Gambia. Children aged 4-59 months without contraindication to vaccination were eligible. Children were not individually randomly assigned; instead, the vaccination teams were randomly assigned (1:1:1) to one of three administration methods. Parents and the field team were not masked, but laboratory personnel were masked. Baseline demographic and anthropometric data were collected from the participants. Public health officers experienced at intradermal immunisation, and nurses without experience, had 2 h of training on each of the administration methods before the campaign. Participants were vaccinated using the administration method in use by the vaccination team in their community. Poliovirus serum neutralising antibodies (SNA) were measured in children aged 24-59 months before and 4 weeks after vaccination. Adverse events and data on injection quality were collected from all participants. The primary outcome was the type 2 immune response rate (seroconversion in seronegative [SNA titre <8] children plus a 4-fold titre rise in seropositive children). Adjusted differences in the immune response between the DSJI or IDA group versus the N&S group were calculated with 97·5% CIs. A margin of -10% was used to define the non-inferiority of DSJI or IDA compared to N&S. Immunogenicity analysis was done per protocol. The trial is registered with ClinicalTrials.govNCT02967783 and has been completed. FINDINGS: Between Oct 28 and Dec 29, 2016, 3189 children aged 4-59 months were recruited, of whom 3170 were eligible. Over 3 days, 2720 children were vaccinated (N&S, 917; IDA, 874; and DSJI, 929). Among 992 children aged 25-59 months with a baseline SNA available, 90·1% (95% CI 86·1-92·9; 281/312) of those vaccinated using the DSJI had an immune response to type 2 compared with 93·8% (90·6-95·8; 331/353) of those vaccinated with N&S and 96·6% (94·0-98·0; 316/327) of those vaccinated with IDA. All (53/53) type 2 seronegative children seroconverted. For polio type 2, non-inferiority was shown for both the IDA (adjusted difference 0·7% [97·5% CI -3·3 to 4·7], unadjusted difference 2·9% [-0·9 to 6·8]) and DSJI (adjusted difference -3·3% [-8·3 to 1·5], unadjusted difference -3·7% [-8·7 to 1·1]) compared with N&S. Non-inferiority was shown for type 1 and 3 for the IDA and DSJI. Neither injection quality nor the training and experience of the vaccinators had an effect on immune response. No safety concerns were reported. INTERPRETATION: In a campaign, intradermal fIPV is safe and generates consistent immune responses that are not dependent on vaccinator experience or injection quality when administered using an N&S, DSJI, or IDA. Countries facing vaccine-derived poliovirus type 2 outbreaks should consider fIPV campaigns to boost population immunity and prevent cases of acute flaccid paralysis. FUNDING: World Health Organization and the Medical Research Council.
引用
- Bashorun AO, Badjie Hydara M, Adigweme I, et al. Intradermal administration of fractional doses of the inactivated poliovirus vaccine in a campaign: a pragmatic, open-label, non-inferiority trial in The Gambia. Lancet Glob Health. 2021. PMID: 34951974. doi:10.1016/S2214-109X(21)00497-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。